ESPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ESPR is not a clear good buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock has some supportive signals, but the overall setup is mixed: technicals are only mildly constructive, insider selling is heavy, no strong proprietary buy signal is present, and the near-term stock pattern points to weakness over the next week and month. I would not call it a strong buy at current levels.
Current price is $2, essentially flat versus the prior close, with regular-session strength offset by a small pre-market decline. MACD histogram is positive and expanding, which supports short-term momentum improvement. RSI_6 at 51 is neutral, so there is no overbought or oversold edge. However, the moving averages are bearish with SMA_200 > SMA_20 > SMA_5, indicating the broader trend is still weak. Price is sitting near pivot support at 1.965, with resistance at 2.097 and 2.178. Overall, the chart shows a short-term bounce inside a still-bearish longer-term trend.
["Citizens raised its price target to $5 from $4 and kept an Outperform rating.", "Q4 results were reported as consistent with the January preannouncement.", "Revenue in 2025/Q4 grew sharply year over year.", "Gross margin improved significantly to 83.46%.", "Options positioning is strongly bullish with very low put-call ratios."]
["No news in the recent week, so there is no fresh event-driven catalyst.", "Insiders are selling aggressively, with selling up 2002.57% over the last month.", "Hedge funds are neutral and not providing a strong institutional buy signal.", "Longer-term technical trend remains bearish with SMA_200 above shorter averages.", "Pattern-based stock trend suggests weakness over the next week and month.", "Net income and EPS declined sharply year over year in the latest quarter."]
In 2025/Q4, Esperion posted revenue of $168.446 million, up 143.73% year over year, which is a strong top-line acceleration. Gross margin also improved to 83.46%, showing better product economics. However, net income fell to $61.831 million and EPS dropped to $0.26, both down sharply year over year, indicating that profitability remains inconsistent despite revenue growth. For a long-term beginner investor, the revenue trend is encouraging but earnings quality is still uneven.
The latest analyst action was bullish: Citizens raised the price target to $5 from $4 and maintained an Outperform rating on 2026-03-13. The analyst cited Q4 results in line with the January preannouncement, execution on Vision 2040 plans, the Corstasis Therapeutics acquisition, and continued pipeline expansion through ESP-2001. Wall Street's pros view is that execution and pipeline progress are improving the story; the cons view is that the stock still lacks a confirmed durable uptrend and insiders are selling heavily.
